ALKYLPHOSPHOCHOLINES - A NEW CLASS OF MEMBRANE-ACTIVE ANTICANCER AGENTS
ALKYLPHOSPHOCHOLINES - A NEW CLASS OF MEMBRANE-ACTIVE ANTICANCER AGENTS
复制标题
DOI：
10.1007/bf00685608
复制
发表时间：
1993-05-01
影响因子：
3
通讯作者：
UNGER, C
中科院分区：
文献类型：
--
作者：
HILGARD, P;KLENNER, T;UNGER, C
结论米替福新和烷基磷酸胆碱类药物的抗肿瘤作用与常规抗癌药物不同。许多证据表明，烷基磷酸胆碱的作用方式与质膜相关的磷酸肌醇代谢有关。抑制磷脂酶C和/或PKC目前被认为是烷基磷酸胆碱的主要生化靶标。考虑到磷酸肌醇代谢和广谱细胞功能（包括分化和侵袭）调节的重要性，米替福新可能成为一种有趣的新药。此外，它可能是一个工具，进一步研究恶性细胞的信号转导的生化途径。
ConclusionFrom the foregoing it is evident that the experimental profile of miltefosine and alkylphosphocholines is different from that of conventional anticancer agents. Much evidence indicated that the mode of action of alkylphosphocholines was related to plasma-membrane-associated phosphoinositide metabolism. Inhibition of phospholipase C and/or PKC is currently thought to be the main biochemical target of alkylphosphocholines. Considering the great importance of both phosphoinositide metabolism and the regulation of a broad spectrum of cellular functions, including differentiation and invasion, miltefosine could become an interesting new drug. In addition, it may be a tool for further studies into the biochemical pathway of signal transduction in malignant cells.